- NASDAQ:AZN added 2.40% on Tuesday alongside a broader market rally.
- Several European countries seek emergency use authorization for AstraZeneca’s COVID-19 vaccine.
- AstraZeneca receives approvals for two additional non-COVID related drugs.
NASDAQ:AZN has now strung together consecutive days of gains as the stock trajectory continues to point upwards for the United Kingdom-based pharmaceutical giant. On Tuesday, AstraZeneca gained 2.40% to close the first trading session of the week at $52.57. While AstraZeneca has lagged behind its American rivals Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) in terms of widespread usage and distribution of its COVID-19 vaccine candidate, the old adage ‘it’s better late than never’ may be what its investors are currently thinking.
AstraZeneca received a further nod of approval from Europe when several countries including Austria, Greece and Denmark have urged the European Medicines Agency to fast track approvals for its vaccine. Austria, in particular, is battling rising cases of the virus, and have officially extended its lockdown to February 7th. The EMA did agree to review the AstraZeneca vaccine data on an expedited basis this month, so these countries should have their answer by the end of January.
AZN stock news
In other news, AstraZeneca has received approvals for its gastric-cancer treatment Enhertu, which it has developed in partnership with Japanese pharmaceutical firm Daiichi Sankyo, after its Phase II results were extremely positive. Enhertu represents the first new treatment for metastatic HER-2 gastric cancer in over a decade. AstraZeneca also received approval to release a new dosage for its non-small cell lung cancer treatment, Imfinzi, which will drastically cut back on patient medical visits, which is especially crucial during the COVID-19 pandemic. The new regiment will see Imfinzi provided to patients in a four-week dosage interval, which represents about half of the visits patients need to make on the current schedule.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
AUD/USD holds steady near 0.6250 ahead of RBA Minutes
The AUD/USD pair trades on a flat note around 0.6250 during the early Asian session on Monday. Traders brace for the Reserve Bank of Australia Minutes released on Tuesday for some insight into the interest rate outlook.
USD/JPY consolidates around 156.50 area; bullish bias remains
USD/JPY holds steady around the mid-156.00s at the start of a new week and for now, seems to have stalled a modest pullback from the 158.00 neighborhood, or over a five-month top touched on Friday. Doubts over when the BoJ could hike rates again and a positive risk tone undermine the safe-haven JPY.
Gold price bulls seem non-committed around $2,620 amid mixed cues
Gold price struggles to capitalize on last week's goodish bounce from a one-month low and oscillates in a range during the Asian session on Monday. Geopolitical risks and trade war fears support the safe-haven XAU/USD. Meanwhile, the Fed's hawkish shift acts as a tailwind for the elevated US bond yields and a bullish USD, capping the non-yielding yellow metal.
Week ahead: No festive cheer for the markets after hawkish Fed
US and Japanese data in focus as markets wind down for Christmas. Gold and stocks bruised by Fed, but can the US dollar extend its gains? Risk of volatility amid thin trading and Treasury auctions.
Bank of England stays on hold, but a dovish front is building
Bank of England rates were maintained at 4.75% today, in line with expectations. However, the 6-3 vote split sent a moderately dovish signal to markets, prompting some dovish repricing and a weaker pound. We remain more dovish than market pricing for 2025.
Best Forex Brokers with Low Spreads
VERIFIED Low spreads are crucial for reducing trading costs. Explore top Forex brokers offering competitive spreads and high leverage. Compare options for EUR/USD, GBP/USD, USD/JPY, and Gold.